Saturday 17 October 2026
Export SDGR’s income statement to Excel — free account
Schrodinger, Inc.
SDGR Healthcare Health Information Services
Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024. In the quarter to June 2026, revenue grew 7.54%, EPS grew 113.6% and free cash flow grew 34.4%, each against the same quarter a year earlier.
22.60
2.88
−11.30%
Follow SDGR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.75 | 5.13 | 3.30 | 4.69 | |
P/FCF ratio |
0.00 | 105.42 | 0.00 | 0.00 | |
P/Operating CF |
(23.87) | (81.60) | (56.66) | (35.64) | |
P/B ratio |
4.60 | 3.61 | 2.68 | 3.69 | |
Price to Tangible BV |
4.66 | 3.66 | 2.72 | 3.75 | |
EV/Sales |
4.19 | 3.56 | 1.70 | 3.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(959.58) | 65.53 | (2.99) | (6.27) | |
EV/FCF |
(316.85) | 73.12 | (2.93) | (6.10) | |
Quick Ratio |
3.16 | 2.68 | 2.68 | 2.65 | |
Current Ratio |
3.25 | 2.75 | 2.74 | 2.71 | |
Net Debt/EBITDA |
9.01 | 25.59 | 8.59 | 10.45 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.39 | 0.33 | 0.37 | 0.39 | |
Operating CF/Net income |
1.89 | (0.49) | 0.25 | (5.70) | |
Capex/Depreciation |
(0.34) | (0.03) | (1.70) | (0.24) | |
Research and Development Expense of Revenue |
78.71% | 47.46% | 74.80% | 69.62% | |
Selling, General and Administrative Expense of Revenue |
57.49% | 37.89% | 58.92% | 56.01% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
19.97% | 11.41% | 15.49% | 14.93% | |
Graham Net Nets |
0.09 | 0.12 | 0.17 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.01%) | (7.94%) | (12.41%) | (4.55%) | |
Free Cash Flow Yield |
(0.23%) | 0.95% | (17.65%) | (10.73%) | |
Revenue per Share |
0.74 | 1.19 | 0.79 | 0.79 | |
Operating CF per Share |
(0.84) | (0.22) | (0.20) | (0.46) | |
Capex per Share |
(0.01) | 0.00 | (0.03) | 0.00 | |
Free Cash Flow per Share |
(0.85) | (0.22) | (0.23) | (0.46) | |
Cash per Share |
5.45 | 5.48 | 5.49 | 5.61 | |
Shareholders Equity per Share |
4.37 | 4.96 | 4.24 | 4.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.37 | 4.96 | 4.24 | 4.40 | |
Free Cash Flow |
(62.36) | (16.13) | (17.34) | (34.43) | |
Working Capital |
326.61 | 330.13 | 294.42 | 296.63 | |
Capital Expenditures |
(0.49) | (0.04) | (2.51) | (0.36) | |
Net Current Asset Value |
139.41 | 157.16 | 143.32 | 159.04 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.04 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
51.11 | 179.86 | 47.25 | 38.95 | |
Average Payables |
10.21 | 11.06 | 11.90 | 9.56 | |
Average Assets |
661.48 | 774.69 | 688.61 | 664.32 | |
Average Common Equity |
385.39 | 392.75 | 343.53 | 335.91 |
Columns are period end dates